Boehringer Ingelheim is pleased to announce that it has received the Frost & Sullivan ‘2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award’.
The analysts recognised Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer that delivers excellence and best practices to its customers and collaboration partners. The Boehringer Ingelheim performance was measured against key competitors in the same market focusing on the following criteria: leverage of competitive intelligence, execution of competitive strategy, impact on market share, competitive brand positioning, and impact on customer satisfaction and value.
“This award is an important recognition for our contract manufacturing organisation and a great confirmation for continued drive to put our customers first,” stated Simon Sturge, corporate senior vice president biopharmaceuticals at Boehringer Ingelheim. “We will not rest on our laurels and will continue to further improve our customer services to also deliver reliable and best quality in the future. With our newly acquired biopharma development and manufacturing facility in Fremont, California, Boehringer Ingelheim has already taken the next important step to further strengthen our global customer orientation and flexibility.”